Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
11/1999
11/18/1999WO1999046283A9 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
11/18/1999WO1999027098A3 A-33 related antigens and their pharmacological uses
11/18/1999CA2331631A1 Benzocarbazoles and indenoindoles as estrogenic agents
11/17/1999EP0957087A2 Enzyme inhibitors
11/17/1999EP0956862A1 Methods of increasing lean tissue mass using ob protein compositions
11/17/1999EP0956302A1 Use of leptin antagonists for treating insulin resistance in type ii diabetes
11/17/1999EP0956296A2 Somatostatin antagonists
11/17/1999CN1046512C Mercaptoacetylamide disulfide derivatives, preparation thereof and medicinal composition containing the same
11/17/1999CN1046511C Benzoylecgonine, ecgonine and ecgonidine derivatives
11/16/1999US5986048 Process for obtaining insulin precursors having correctly bonded cystine bridges
11/16/1999US5985862 Treating undesired smooth muscle contractions and inflammatory diseases
11/16/1999US5985851 Use of hyaluronic acid or its derivatives in peritoneal dialysis and formulations thereof
11/16/1999US5985850 Comprising a therapeutically effective amount of an agent to treat a disease or condition involving underperfused tissue and pathological tissue in humans and a form of hyaluronic acid as transport agent
11/16/1999CA2002864C (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
11/11/1999WO1999057263A1 Modifying the expression of the fsh beta gene by homologous recombination
11/11/1999WO1999057117A2 Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
11/11/1999CA2328506A1 Modifying the expression of the fsh beta gene by homologous recombination
11/10/1999EP0954317A2 Use of 7 apha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
11/10/1999EP0954302A1 Therapeutic methods and compositions involving isoflavones
11/10/1999CN1234803A N heterocyclic substituted adenosine derivatives
11/09/1999US5981599 Inorganic ion receptor active compounds
11/04/1999WO1999055845A1 Cellular and animal models for diseases associated with altered mitochondrial function
11/04/1999WO1999055358A1 Methods for treating hot flashes and gynaecomastia
11/04/1999WO1998027113A9 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
11/04/1999CA2329941A1 Methods for treating hot flashes and gynaecomastia
11/03/1999EP0744944B1 Sexual steroid-containing transdermal therapeutic systems
11/03/1999CN1233952A Nasal administration of desmopressin
11/02/1999US5977365 Heterocyclic compound having anti-diabetic activity
11/02/1999US5977178 Compounds with growth hormone releasing properties
11/02/1999US5977126 Antiangrogens, enzyme inhbitors
11/02/1999US5977069 Mixture of growth hormone and asparagine as stabilizer
10/1999
10/28/1999WO1999054459A2 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/28/1999WO1999053910A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
10/28/1999WO1999042127A3 Receptor derived peptides as modulators of receptor activity
10/28/1999CA2326823A1 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/27/1999CN1233173A Therapeutic methods and compositions involving isoflavones
10/26/1999US5973006 Nervous system disorders; alzheimer's disease; huntington disease; parkinson's disease
10/26/1999US5972921 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
10/26/1999US5972917 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders
10/26/1999US5972898 Erythromycin a derivatives as lutenizing hormone releasing hormone (lhrh) antagonists, and methods of their preparation
10/26/1999CA2183320C Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
10/26/1999CA2177576C Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052890A1 Chromanone and thiochromanone derivatives
10/21/1999CA2327782A1 Azabicyclic 5ht1 receptor ligands
10/20/1999CN1232499A Human growth gene and short stature gene region
10/20/1999CN1232470A GLP-1 derivs.
10/20/1999CN1232448A Vitamin D analogues
10/20/1999CN1232390A Medicament product
10/19/1999US5969095 Analogs of parathyroid hormone
10/19/1999US5969093 Secreted proteins
10/19/1999US5968978 Antiarrythmia agents, antiischemic agents, inhibit proliferation of cells
10/19/1999US5968924 Benzo-fused lactams promote release of growth hormone
10/19/1999US5968819 DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
10/19/1999US5968518 Composition and method for treating premenstrual syndrome
10/19/1999CA2197298C Novel pyrimidine derivatives and processes for the preparation thereof
10/14/1999WO1999051596A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051595A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051234A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051233A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051232A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051231A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999043705A8 N-terminally truncated glp-1 derivatives
10/14/1999WO1999037604A3 Dialkyl ureas as calcitonin mimetics
10/14/1999CA2326185A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326184A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326143A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326140A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326139A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2325995A1 Antagonists of gonadotropin releasing hormone
10/13/1999EP0948541A2 Analogs of parathyroid hormone
10/13/1999EP0948521A1 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
10/13/1999EP0948520A1 Tissue specific expression of retinoblastoma protein
10/13/1999EP0775339B1 Current-to-pressure transducer with selectable, adjustable input filter
10/13/1999CN1231672A Conformationally constrained backbone cyclized somatostatin analogs
10/13/1999CN1231670A 7 'alpha'-('xi'-aminoalkyl) estratrienes, process for preparing the same, pharmaceutical preparations containing the same, and their use for preparing medicaments
10/13/1999CN1231666A Tricyclic benzazepine vasopressin antagonists
10/13/1999CN1231177A Novel contraceptive compositions and preparation process thereof
10/12/1999US5965623 Anti-glucocorticoid drug
10/12/1999US5965606 Retinoid receptors, 2-fluoro-4-(2',2',4',4'-tetramethyl-8'-trifluoromethylchroman-6' -yl)carbamoyl benzoic acid for treating monocytic leukemia
10/12/1999US5965584 Pharmaceutical composition
10/12/1999US5965564 Enantiomerically pure hydroxylated xanthine compounds
10/12/1999US5965521 Pulsatile delivery of leptin receptor ligands
10/07/1999WO1999050658A2 Methods and compounds for modulating nuclear receptor activity
10/07/1999WO1999050276A1 3',3'-n-bis-substituted macrolide lhrh antagonists
10/07/1999WO1999050275A2 Macrolide lhrh antagonists
10/07/1999CA2325521A1 Macrolide lhrh antagonists
10/07/1999CA2325519A1 3',3'-n-bis-substituted macrolide lhrh antagonists
10/07/1999CA2324060A1 Methods and compounds for modulating nuclear receptor activity
10/06/1999EP0947522A2 Process for the preparation of oenotheine B from Epilobium Parviflorum
10/06/1999EP0946721A1 Human growth gene and short stature gene region
10/06/1999EP0946595A2 Melanocortins
10/06/1999CN1230966A Use of leptin antagonists for treating insulin resistance in type II diabetes
10/05/1999US5962698 Plasminogen activator inhibitor
10/05/1999US5962682 Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
10/05/1999US5962530 Neuropeptide y antagonist
10/05/1999US5962479 Psychological and nervous sytem disorders
10/05/1999US5962470 Heterocyclic compounds having anti-diabetic activity and their use
10/05/1999US5962411 Human growth hormone variants and methods of administering same
10/05/1999US5962409 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
1 ... 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 ... 290